New drug cocktail aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07054242
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests whether combining two drugs (sacituzumab tirumotecan and pembrolizumab) before surgery can eliminate all signs of cancer in people with stage II or III triple-negative breast cancer. About 52 participants who have not had prior treatment will receive the drugs for 8 to 18 weeks, then have surgery. The main goal is to see how many achieve a complete response (no cancer left in the breast or lymph nodes).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Breast Surgery, Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.